Calpo

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Calpo

Property Description
Active ingredient Paracetamol (Acetaminophen)
Form Oral Suspension, Tablets, Drops, Suppositories
Pharmacological class Analgesic, Antipyretic
Common use Relief of pain and fever
Origin Synthetic (p-aminophenol derivative)

Calpol is a recognized brand of medicine whose primary active ingredient is Paracetamol, which is chemically known as Acetaminophen. The brand is manufactured by Johnson & Johnson and is distinctively positioned for the paediatric population. It is a synthetic compound classified as an analgesic and an antipyretic, meaning its core function is to reduce pain and fever.


What Type of Medicine is Calpol?

Calpol is fundamentally defined by its active component, Paracetamol, which is a p-aminophenol derivative. The drug is classified as both an analgesic (pain reliever) and an antipyretic (fever reducer). This medicine is widely available as an Over-The-Counter (OTC) product. Paracetamol serves a therapeutic role in providing pain and fever relief and is recognized as a first-line treatment for managing general discomfort and elevated temperatures.


Composition and Available Drug Forms

The medicine is a single-ingredient product where Paracetamol serves as the sole active pharmaceutical component. To accommodate various patient needs, particularly in the paediatric population, it is prepared in several key dosage forms, notably the liquid Oral Suspension which is often flavored (e.g., strawberry) to increase compliance in children. Other forms include Oral Drops, Tablets, Oral Powder, and Suppositories, with the primary route of administration being oral. These various formulations are designed so that the product can be appropriately used across the relevant population. The liquid preparations commonly rely on an aqueous vehicle for ease of ingestion, while tablets utilize a solid matrix.


General Therapeutic Purpose

The overarching purpose of Calpol is to provide effective symptomatic relief from fever and mild-to-moderate pain. Its therapeutic function arises from its dual classification: as an antipyretic, it works to normalize an elevated body temperature, and as an analgesic, it lessens the sensation of pain. This combined action makes the medicine a standard option for managing generalized discomfort, such as the feverishness associated with minor infections, or discomfort following routine vaccinations.

Regulatory References

  1. United States Adopted Names (USAN)
  2. National Institutes of Health (NIH) MedlinePlus

What side effects are possible with Calpo?

Adverse Reactions and Safety Classifications

Adverse effects associated with the active ingredient, Paracetamol, are generally rare when used as directed. Official regulatory documents categorize reactions based on the body system involved and their frequency.

System-Organ Classes and Frequency

Side effects are grouped by system-organ class (SOC), with documented reactions involving the Immune System Disorders, Blood and Lymphatic System Disorders, Hepatobiliary Disorders, and Skin and Subcutaneous Tissue Disorders.

Classification Examples of Documented Reactions
Rare Hypotension, increased hepatic transaminase levels.
Very Rare Thrombocytopenia, agranulocytosis, severe cutaneous reactions (e.g., SJS, TEN), anaphylaxis.
Not Known Reactions reported post-marketing, such as angioedema.

Serious Safety Constraints

The most critical safety constraint documented in regulatory labeling is the potential for acute hepatic failure (severe liver damage), which is primarily associated with use exceeding the recommended daily limits. Severe Cutaneous Adverse Reactions (SCARs) are also listed as rare but potentially life-threatening events.

Population-Specific Notes

The regulatory profile specifies constraints for certain patient groups. The medicine is contraindicated in cases of pre-existing severe active liver disease. Caution is also noted for individuals with severe renal impairment and those with a history of chronic heavy alcohol use due to an elevated risk of toxicity.

Regulatory Restrictions

Official labeling contains a mandatory restriction: it must not be used concurrently with any other medicine containing Paracetamol (Acetaminophen) due to the serious risk of overdose and subsequent severe liver damage.

Overdose and Emergency Response

Overdose and When to Seek Help

Immediate medical attention must be sought in the event of any suspected overdose of Calpol (Paracetamol/Acetaminophen), even if the patient feels well or has no symptoms. The risk of severe, delayed liver damage exists without immediate clinical signs.

Documented Overdose Profile

Stage Documented Manifestations Critical Outcomes
Initial (0-24 hours) Nausea, vomiting, pallor, anorexia, and abdominal pain. May be asymptomatic. Risk of delayed Hepatocellular necrosis begins.
Delayed (12-48+ hours) Clinical signs of liver damage, elevated liver enzymes, coagulopathy. Liver failure, metabolic acidosis, coma, and death.

Emergency Regulatory Actions

The most effective management requires rapid intervention. The antidote, N-acetylcysteine (NAC), should be administered immediately in the hospital setting. The maximum protective effect of the antidote is obtained when treatment is initiated within 8 hours of acute overdose.

Patients with certain conditions, including chronic malnutrition, chronic alcohol use, or those taking enzyme-inducing drugs, are listed in official documents as having a higher risk of severe hepatotoxicity following an overdose.

Therapeutic Uses of Calpo

Main uses and benefits of Calpol

Calpol is a medication widely used to manage mild-to-moderate pain and reduce elevated body temperatures. Its primary active ingredient is paracetamol, which works by affecting chemical messengers in the body that signal pain and regulate temperature.

Pain relief

Calpol is used to alleviate various types of discomfort in infants and children. It is effective for treating common aches including:

  • Teething pain and toothache: Provides relief from the discomfort associated with emerging teeth or dental issues.
  • Headaches: Helps reduce the intensity of tension or minor headaches.
  • Sore throats: Soothes the pain often associated with colds and respiratory infections.
  • Earache: Manages the localized pain often caused by middle ear congestion or inflammation.
  • Post-vaccination discomfort: Addresses the localized soreness or general malaise that can follow childhood immunizations.
  • Musculoskeletal aches: Relieves minor aches and pains associated with physical activity or minor injuries.

Fever reduction

One of the most frequent applications of Calpol is the management of pyrexia, or fever. By acting on the temperature-regulating center of the brain, paracetamol helps to lower a high temperature back toward a normal range. This is particularly beneficial during:

  • Colds and influenza: Reducing a fever can help a child feel more comfortable and less lethargic during viral illnesses.
  • General infections: It serves as a supportive treatment to manage the febrile response while the body's immune system addresses the underlying cause.

Benefits of use

As a liquid-based medication, Calpol offers specific benefits for pediatric care. The formulations are designed to be palatable for children, which simplifies administration for caregivers. Because it does not contain aspirin, it is considered a suitable option for children, avoiding the specific risks associated with aspirin use in younger populations. When used appropriately, it provides a predictable onset of action to improve the overall comfort and well-being of the patient during acute illness.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

The eligibility for using Calpol, which contains Paracetamol (Acetaminophen), is strictly defined by regulatory authorities based on patient age, pre-existing health conditions, and physiological status.

Eligibility Scope

Eligibility Group Status (Regulatory Statement)
Contraindicated Populations MUST NOT USE: Individuals with known hypersensitivity to Paracetamol or any excipient, or those taking other products containing Paracetamol [Source 1.2, 2.3]. Use is also contraindicated in patients with severe hepatic impairment (severe liver disease) [Source 2.1, 2.2].
Age-Related Eligibility MINIMUM AGE: The medicine is generally not recommended for routine use in infants under 2 to 3 months of age [Source 1.2, 3.2]. It is approved for use in paediatric patients above this threshold, as well as adults and adolescents [Source 1.1, 1.5].
Conditional Use CAUTION/RESTRICTION: Use requires caution in patients with severe renal impairment or mild-to-moderate hepatic impairment [Source 1.4, 2.2]. Caution is also advised for patients with chronic alcoholism or severe malnutrition (conditions predisposing to glutathione depletion) [Source 1.4, 2.3].
Maternal Status PERMITTED WITH CONDITIONS: Regulatory bodies state that Paracetamol is permitted during pregnancy and lactation when clinically necessary, but it must be used at the lowest effective dose for the shortest possible duration [Source 1.4, 4.1].

Connection to the Overall Eligibility Profile

Official regulatory documents establish clear absolute prohibitions for individuals with hypersensitivity or severe liver disease, which is the cornerstone of non-eligibility. They define minimum age thresholds for use in children and classify use as conditional for adults with compromised renal or hepatic function, structuring the entire eligibility profile around pre-existing physiological status and patient demographics.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Official regulatory documentation structures the interaction profile of Calpol (Paracetamol/Acetaminophen) around how other substances alter its exposure or enhance a specific risk.

The most severe restriction is the formal contraindication against co-administering Calpol with any other medicine containing paracetamol or acetaminophen. This is to prevent exceeding the maximum daily dose and to mitigate the risk of severe hepatic injury or liver failure.

Documented Interaction Patterns

Interaction Type Interacting Substance/Class Official Regulatory Effect
Clearance/Metabolism Probenecid Reduces clearance by approximately 50% via inhibition of conjugation.
Enzyme Inducers (e.g., Phenytoin, Carbamazepine) Increases the formation of hepatotoxic metabolites.
Absorption/Exposure Metoclopramide or Domperidone Increases the speed of paracetamol absorption.
Colestyramine Reduces the extent of paracetamol absorption.
Pharmacodynamic Risk Oral Anticoagulants (e.g., Warfarin) Prolonged regular use enhances the anticoagulant effect.
Flucloxacillin Associated with the risk of High Anion Gap Metabolic Acidosis (HAGMA).

Risk of liver damage is noted as increased with chronic alcohol consumption or consumption of three or more alcoholic drinks per day. This risk is also higher in individuals with underlying liver disease, according to official warnings.

Mechanism of Action

The effect of Calpol stems from the action of its ingredient, paracetamol, which primarily targets key signaling pathways within the central nervous system (CNS) to influence central neural signaling pathways and core thermoregulatory mechanisms.

Central Inhibition of Prostaglandin Production

This domain covers the molecular action where the drug inhibits cyclooxygenase ( COX) enzyme activity primarily in the brain and spinal cord, restricting the synthesis of the signaling molecule PGE2. The suppression of PGE2 production correlates with reduced central signal transmission and neuronal sensitivity, leading to a decreased responsiveness of nociceptive pathways to peripheral stimuli.

Hypothalamic Thermoregulatory Reset

This domain addresses the drug's specific action on the thermoregulatory center located in the hypothalamus of the brain. By reducing the influence of PGE2 on this center, the drug effectively resets the body's elevated temperature set point. The adjustment of the hypothalamic set point activates heat-dissipating mechanisms, such as vasodilation and sweating, which drive heat transfer out of the body.

Dosage and Administration Information

How to use Calpol

The administration of Paracetamol, the active ingredient in Calpol, is governed by structured usage protocols that detail its proper application. The medicine is used via the oral and rectal routes, with the intravenous infusion route specified for acute use in hospital settings, establishing its scope of administration.

Dosing is standardized by patient weight and age, establishing an absolute maximum daily intake of 4000 mg for adults and adolescents weighing 50 kg or more. For pediatric use, a single dose is typically calculated in the range of 10 mg/kg to 15 mg/kg of the active ingredient. The standard schedule mandates a minimum interval of four hours between administrations, restricting use to a maximum of four doses in a 24-hour period for the majority of oral formulations.

This frequency is subject to necessary adjustment for specific populations, as patients with severe renal impairment require the interval to be prolonged to six or eight hours, depending on the severity. Proper preparation dictates that oral suspensions must be shaken well prior to measurement, and only the product's dosing device should be used to ensure volume accuracy. Use is intended to be short-term, generally limited to three consecutive days of self-medication before professional evaluation is warranted.

Recent Clinical Evidence

Research Evidence: Overview of Studies

Phase I: Initial Research and Tolerability

Phase I trials primarily focused on understanding how the drug was processed by the body and gathering initial data on participant tolerability.

The studies documented the occurrence of adverse events among participants and tracked participant tolerability. Adverse events documented in the studies included events across a range of severities. Research protocols typically initiated the treatment with the lowest dose, increasing slowly to monitor for participant response.

Phase II: Preliminary Symptom Assessment and Dosing

Studies assessed whether the treatment was associated with changes in symptoms among individuals with mild to moderate symptoms. This phase was designed to find a dosage range for further investigation.

  • Symptom Change: Research examined whether the treatment was associated with changes in participant-reported duration and severity of flare-ups. Outcomes were measured using standard scoring instruments.
  • Timeframe: Studies tracked changes in participant symptoms over time, including the initial timeline and duration of any observed changes. Findings varied between participant groups.
  • Combination: Studies evaluated the treatment in combination with physical therapy and tracked participant outcomes related to movement.

Participants in the studies were asked to monitor their symptoms closely and record any changes in a diary. The preliminary findings suggested a need for larger, controlled trials.

Phase III: Comparative Outcomes

Larger randomized controlled trials (RCTs) were conducted to compare the treatment to a placebo or an active comparator.

  • Comparative Research: Research has explored whether this approach offered different outcomes compared to existing therapies over a six-month period.
  • Adherence and Cessation: Research protocols tracked participant adherence and included instructions on how participants should cease use of the drug.
  • Long-term Tracking: Studies tracked the rate of remission among participants receiving this therapy for up to one year. Outcomes measured in the studies generally did not extend beyond 12 months.

Final conclusions on treatment outcomes and effectiveness in the studies are dependent on a comprehensive review of all trial data.

Key Studies & References The efficacy and safety of paracetamol for pain relief: an overview of systematic reviews | The Medical Journal of Australia

Frequently Asked Questions (FAQ)

Common questions about Calpol (FAQ)


Q: Is Calpol the same as other brands of paracetamol?

Calpol is a brand name for a medicine containing the active ingredient paracetamol (also known as acetaminophen). While the primary medicinal component is the same as in other paracetamol brands, Calpol formulations, such as the oral suspension, contain different inactive ingredients (excipients), including unique flavorings, colors, or specific sweeteners, as detailed in the official product label.


Q: How long does it usually take for Calpol to start working?

According to official pharmacokinetic information, the active ingredient is absorbed into the body fairly quickly. Peak concentrations in the blood are generally documented to occur anywhere from 30 minutes to two hours after the medicine is taken. The time to reach peak concentrations, which is associated with the onset of the main effect, is typically within one to three hours.


Q: How long do the effects of Calpol generally last?

Studies and official information indicate that the duration of action for the pain-relieving and fever-reducing effects is generally documented to be three to four hours on average. The recommended dosage interval is established to maintain relief while preventing administration that exceeds official limits.


Q: What is the difference between Calpol SixPlus and Calpol Infant Suspension?

The primary difference lies in the concentration of the active ingredient, paracetamol. Official product labeling specifies that the Six Plus Oral Suspension typically contains a higher amount of paracetamol per 5 ml dose than the standard infant formulations. This difference means the products are formulated for use in different age and weight categories.


Q: Does Calpol contain sugar or artificial sweeteners?

Specific regulatory labels for liquid formulations, especially those labeled 'Sugar/Colour Free,' list various excipients (inactive ingredients) such as the sweeteners Maltitol and Sorbitol. Regulatory warnings mention that these ingredients may be associated with gastrointestinal discomfort or a mild laxative effect in certain individuals. Other standard Calpol formulations may contain sucrose (sugar).


Q: What should I do if a dose of Calpol is forgotten?

Official regulatory instructions advise that if a dose is forgotten, the next step is to take the subsequent dose when it is genuinely needed. The instruction strictly cautions against using a double dose to make up for a missed dose, and respecting the minimum time interval between administrations is necessary.


Q: Can Calpol cause stomach upset?

While adverse effects are rare when used as directed, safety reviews have documented reports of reactions such as nausea, vomiting, or stomach discomfort. These symptoms are often reported in the context of use exceeding the recommended dosage limits, as noted in the product information.


Q: Can Calpol be used for teething pain?

The medicine is indicated for the symptomatic treatment of mild to moderate pain. Official regulatory documents list pain relief as the general purpose. The official documents for the active ingredient do not specifically list teething pain as a primary indication, and product labeling does not explicitly list every potential source of discomfort.


Q: How is Calpol different from ibuprofen-based products?

Official drug classification distinguishes Calpol's active ingredient, paracetamol, as a Miscellaneous Analgesic and Antipyretic that primarily works in the central nervous system. In contrast, ibuprofen is classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID). NSAIDs are defined as acting both centrally and peripherally (in the body) to reduce inflammation, pain, and fever.


Q: Does Calpol affect sleep patterns?

Drowsiness or sleep disturbances are not listed among the documented common side effects of the active ingredient, paracetamol, when used as directed. Official product information notes that drowsiness or unconsciousness can be associated with overdose or a serious adverse event.


Q: What is the typical concentration of the active ingredient in Calpol suspension?

Official regulatory documents define the standard strengths of liquid formulations. Common oral suspension concentrations include 120 mg of paracetamol per 5 ml for infant preparations and 250 mg of paracetamol per 5 ml for products intended for older children. The concentration should always be confirmed by reviewing the specific product packaging.


Q: Can Calpol be taken on an empty stomach?

Official regulatory documentation on pharmacokinetics does not contain a general instruction prohibiting the use of Calpol with or without food. However, official drug-interaction information notes that certain co-administered medicines (such as colestyramine) may reduce the extent of absorption of paracetamol in the gut.


Q: Does Calpol contain any known allergens?

The specific formulation lists various non-active ingredients (excipients) which may include preservatives, such as methyl parahydroxybenzoate ( E218 ) and propyl parahydroxybenzoate ( E216 ). Regulatory documents indicate these substances may be associated with allergic reactions, which may be delayed. Individuals with known hypersensitivity to any excipient listed in the label should avoid use.


Q: How do regulatory agencies track adverse events for Calpol?

Regulatory agencies globally, such as the FDA and the MHRA, manage national pharmacovigilance programs. These systems enable healthcare professionals and patients to report suspected adverse reactions via national surveillance and reporting mechanisms, which track events following the product's authorization.


Q: What are the typical ingredients besides the active pharmaceutical ingredient (API)?

Official product labeling (SmPCs) for liquid formulations detail the non-active ingredients, or excipients. These commonly include purified water, sweeteners (like maltitol or sorbitol), various colorings and flavorings, and preservatives (such as the parahydroxybenzoates) necessary to stabilize the liquid and make it palatable for pediatric use.


Q: Is Calpol considered a non-steroidal anti-inflammatory drug (NSAID)?

Based on official pharmacological classification, Calpol's active ingredient, paracetamol, is not classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID). It is designated as an Analgesic (pain reliever) and an Antipyretic (fever reducer) that acts primarily within the central nervous system.


Q: Can Calpol be taken alongside cold and flu remedies?

The most significant regulatory caution is the formal contraindication against using Calpol with any other medicine that contains paracetamol or acetaminophen. Due to the potential for co-administered products to contain paracetamol, reviewing all ingredient lists is necessary to prevent use that exceeds the maximum daily dose.


Q: Are there any food or drink items that should be avoided when taking Calpol?

Official safety warnings highlight that the risk of liver damage may be increased when the medicine is used in conjunction with chronic, heavy alcohol use. There is no general regulatory instruction prohibiting the medicine with standard food intake.


Q: Why is it important not to exceed the recommended frequency of Calpol use?

Official guidelines emphasize adherence to the minimum four-hour interval and maximum daily limit to prevent the accumulation of the active ingredient in the body. Use that exceeds the recommended frequency or dosage is strongly associated with the risk of acute hepatic failure (severe liver damage).


Q: What research evidence supports the use of Calpol for fever reduction?

Clinical trial data, as reviewed by regulatory bodies, confirms the medicine's function as an antipyretic. Research evidence supports the association between the active ingredient and the reduction of elevated body temperature.


Q: Why is Calpol commonly used in children?

Calpol is distinctively positioned for the paediatric population due to its established safety profile for use in children older than two to three months and its formulation into easy-to-administer liquid forms. The available flavored oral suspensions help to improve compliance and acceptance among children.


Q: Are different flavors of Calpol considered medically equivalent?

The different flavor variations of the oral suspension are considered pharmaceutically equivalent as the active ingredient (paracetamol) and the stated concentration remain the same. The flavorings are part of the non-active ingredients (excipients) and do not alter the medicinal effect of the product.


Q: Is there a generic version of Calpol available?

Calpol is a specific brand name, but the active ingredient, paracetamol, is a widely available compound. Consequently, the same active ingredient is sold under many generic or non-branded product names and is formulated by various manufacturers, offering pharmaceutically equivalent alternatives.


Q: Do clinical trials confirm the stated duration of Calpol's effect?

Large-scale clinical research, including Phase III randomized controlled trials, tracked the changes in participant symptoms over time, including the initial timeline and the duration of observed effects. Official regulatory documents rely on this research to support the common guidance that the effects typically last for three to four hours.


Q: Does Calpol affect a patient's immune system?

Official documents categorize potential adverse reactions, and rare events involving the immune system are listed. The medicine is primarily noted for its effects on pain and fever relief, and is not generally described as having a direct effect on the immune system.

How should Calpo be stored and disposed of?

How to Store and Dispose of Calpol: Official Regulatory Requirements

The official labeling for Calpol (Paracetamol) liquid formulations mandates specific conditions for storage and disposal to ensure product stability and safety.

Storage Conditions

Requirement Details
Temperature Store below 25°C or not exceeding 30°C; must not be refrigerated or frozen
Protection Must be stored protected from light and moisture
Packaging Keep in the original package and ensure the bottle is kept tightly closed
Child Safety Mandatory instruction to keep out of the sight and reach of children

Disposal Instructions

Official documents prohibit disposing of the medicine via wastewater or household waste. Unused or expired Calpol must be disposed of in accordance with local requirements. The authorized instruction advises consulting a pharmacist for guidance on proper disposal procedures.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Calpo found in:

A-Z Index: